Background: Interest in the anesthetic use of xenon, a noble gas, has waxed and waned for decades, and the clinical effects of xenon are still debated. We performed a meta-analysis to compare the clinical efficacy of xenon with that of propofol.
Introduction
Xenon, which was first used as a general anesthetic in 1951, [1] is an alternative to currently used anesthetics. While xenon has a high cost, it also has many advantages over other anesthetics, such as low blood-gas and brain-blood coefficients, rapid induction and recovery, almost no respiratory, hepatic or renal toxicity, stable hemodynamics, and effective neuroprotective and environmentally friendly properties. [2] During the past decade, a number of randomized controlled trials (RCTs) have been published that have compared the clinical efficacies of xenon and other volatile or intravenous anesthetics. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Although one meta-analysis [2] has summarized these individual studies, it contained some specific errors and failed to include important clinical data related to propofol.
Propofol, one of the most widely used intravenous anesthetics, has a fast induction and recovery, is associated with short stays in postanesthesia care units (PACUs), and has few effects on patient movement. [21] When used inappropriately, propofol can cause hypotension, bradycardia, injection pain, and respiratory depression. [21, 22] Clinically, the bispectral index (BIS) is a valuable method for monitoring the anesthetic effect of propofol. [23] By carefully analysing the available data, we performed a metaanalysis of published RCTs to compare the clinical efficacies of xenon and propofol.
Methods

Search strategy
The present study was performed by searching the PubMed, Embase, and Cochrane Library databases to retrieve relevant studies that were published through December 2017 and described clinical comparisons between xenon and propofol. All analyses were based on previous published studies, thus no Editor: Chien-Kun Ting.
ethical approval and patient consent are required. The search was restricted to articles published in the English language. The initial search process involved the terms ("Xenon") and ("propofol" or "ICI 35868," or "2,6-diisopropylphenol") and ("anesthesi * " or "anaesthesi * "). Moreover, we excluded 2 retracted articles. [24, 25] The authors were not contacted for any additional information, and our search results did not include any unpublished studies.
Study selection
The first step was to screen potential abstracts and titles. Full-text reviews were performed in the second round. We defined the trials as eligible if they conformed to the following inclusion criteria: comparisons between xenon and propofol; RCTs; the outcomes of interest were time in the PACU, the influence of xenon on nondepolarizing muscular relaxants, BIS index, hemodynamic effects, and side effects, such as hypotension, bradycardia, hypertension and postoperative nausea and vomiting (PONV). For more details, see Figure 1 .
Data collection and risk of bias
YX and HF independently performed the electronic search and data extraction. Arguments were settled by a third investigator (CJ). The data were extracted according to the following standard form: last name of the first author, publication year, number of patients, the dosage and time of the anesthetics, and the type of surgery.
With the help of the Cochrane collaboration's tools, we established a table to determine "risk of bias" of the selected trials according to the following 6 parameters: adequate sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessments, incomplete outcome data, and selective outcome reporting. We labeled each parameter as "low", "high," or "unclear" to clarify the risk of bias.
Statistical analysis
We used Review Manager 5.3 software (Cochrane Collaboration, Copenhagen) to perform all statistical analyses. Dichotomous outcomes are presented as relative risks (RRs), and continuous data are shown as the weighted mean difference (WMD). Both include 95% confidence intervals (CIs). If significant heterogeneity was detected, the pooled estimates were calculated using a random-effects model. Otherwise, a fixed effects model was used, and z tests were used to assess the effects. Continuous results are shown as the mean ± standard deviation (SD), and the chi-square test and I 2 statistic were used to test for heterogeneity among the trials. P values < .05 were regarded as statistically significant. Figure 1 shows an outline of the literature search and selection process. After duplicates were deleted, 67 studies were identified. After the article titles and abstracts were examined, 17 studies were included. Moreover, 2 retracted studies, [24, 25] one study for which the full text was lost [14] and one study that was not an RCT, [26] were excluded. Finally, 13 studies that included a total of 817 patients were selected for the analysis. [3] [4] [5] [6] [7] [8] [9] [10] 13, [15] [16] [17] 20] The evaluated trials included reports that were published through December 2017. The baseline characteristics of the pooled studies are summarized in Table 1 , which includes patient age and the American Society of Anesthesiologists (ASA) status, which anesthetic drugs were administered and what type of surgery was used, and the results that are relevant to the analysis. Table 2 includes the risk assessment.
Results
3.1. Primary outcome 3.1.1. BIS values. BIS values were assessed in 4 studies. [4] [5] [6] 10] All studies showed that there was a lower index in the xenon group than in the propofol group. The pooled mean difference between the xenon and propofol groups was calculated (WMD: À6.26, 95% CI: À11.33 to À1.18, P = .02; Fig. 2 ) and was significantly different between the 2 groups.
Influence on nondepolarizing muscular relaxants.
Two studies assessed how nondepolarizing muscle relaxation was affected by xenon. [15, 16] Both studies included the time of onset, duration (T 25 ), clinical recovery (T 25-0.8 ), and recovery index (T ). No significant differences were observed between the xenon group and the propofol group (Table 3) .
3.1.3. PACU length. The data are expressed as the mean (±SD) duration time, and the length of stay in the PACU after xenon treatment was evaluated in 3 trials. [8] [9] [10] No significant difference was found between the xenon and propofol groups (WMD: À0.94, 95% CI: À8.79 to 6.91, P = .81; Fig. 3 ).
3.2. Secondary outcomes 3.2.1. Perioperative complications. We analysed three studies [5, 8, 9 ] that compared PONV and 2 studies [5, 10] that investigated Abramo et al [5] 2012 Unclear Unclear High Low Low Low Baumert et al [5] 2008
Unclear Unclear High Low High High Baumert et al [6] 2007 Unclear Unclear High Low Low High Baumert et al [6] 2005 Unclear Unclear High Low High High Bein et al [7] 2005 Unclear Unclear High Low Low Low Bein et al [20] 2004 Low Unclear High Low Low Low Coburn et al [8] 2008
Low Low High Low Low Low Coburn et al [9] 2005 Unclear Unclear High High Low Low Coburn et al [10] 2005 Low Low High Low High High Hanss et al [13] 2006
Low Unclear Unclear Low Low Low Kunitz et al [16] 2005 Low Low High High Low High Kunitz et al [15] 2004 Low Low High High Low High Rasmussen et al [17] 2006
High Unclear High Low Low Low Baumert et al [6] 2007 >40/III-IV 60%(0.8MAC) (no. 13) 5 mg/kg/h (no. 13) Noncardiac, nonthoracic surgery BIS value, MAP, HR Baumert et al [4] 2005 >18/III-IV 60%-65% (0.8MAC) (no. 12)
3 mg/kg/h (no. 14) Implantation of a cardioverterdefibrillator (ICD) BIS value, HR, MAP Bein et al [7] 2005 ?/ III 55%-60% (0.8MAC) (no. 20) [13] 2006
?/II-IV 60%(0.8MAC) (no. 22) 3-6 mg/kg/h (no. 22) Abdominal aortic surgery HR, MAP Kunitz et al [16] 2005 18-60/I-II 60%(0.8MAC) (no. 21) 0.09-0.13 mg/kg/min (no. 21) ? Neuromuscular monitoring (mivacurium) Kunitz et al [15] 2004 18-60/I-II 60%(0.8MAC) (no. 20) 0.06-0.12 mg/kg/min (no. 20)
? Neuromuscular monitoring (rocuronium) Rasmussen et al [17] 2006 >60/I-II 50%-70% (0.8MAC) (no. 21) . PACU stay length in the xenon group versus that in the propofol groups. IV = inverse variance, fixed = fixed effect, 95% CI = 95% confidence interval. Table 3 Influence of xenon on nondepolarizing neuromuscular relaxants. hypotension, hypertension, and bradycardia between xenon-and propofol-treated patients. There was no significant difference in the incidence of PONV (RR: 2.01, 95% CI: 0.79-5.11, P = .14; Fig. 4A ), hypertension (RR: 1.27, 95% CI: 0.73-2.21, P = .39; Fig. 4B ), hypotension (RR: 0.62, 95% CI: 0.27-1.40, P = .25; Fig. 4C ), or bradycardia (RR: 1.00, 95% CI: 0.36-2.74, P = 1.00; Fig. 4D ) between the groups.
Hemodynamic changes.
Eight papers that included a total of 413 patients reported values for mean arterial blood pressure (MAP) and heart rate (HR). [4] [5] [6] [7] 10, 13, 17, 20] Higher MAP (WMD:7.00, 95% CI: 2.32-11.68, P = .003; Fig. 5A ) and lower HR (WMD: À9.45, 95% CI: À12.28 to À6.63, P < .00001; Fig. 5B ) values were observed in the xenon group than in the propofol group.
Discussion
The present meta-analysis included 13 studies. Our objective was to compare the BIS index, the effects on nondepolarizing muscular relaxants, the length of stay in the PACU, hemodynamic changes and perioperative complications between patients who were administered xenon versus propofol as a general anesthetic.
Our analysis revealed that patients who were administered xenon had a higher MAP, lower HR, and lower BIS index than patients administered propofol. However, there was no difference between the 2 treatment groups in the effects of the treatments on nondepolarizing muscular relaxants, the length of stay in the PACU or perioperative complications.
Similar to a previous meta-analysis, [2] we compared hemodynamic changes, perioperative complications and PACU stay length between the xenon and propofol groups. Although some data corrections were made, such as the correction that 20 and not 13 patients were in each group that was used to compare the incidences of PONV, [2, 8] we reached similar conclusions. Compared to a previous analysis, [2] we added one more study [15] and detected additional vital data, including BIS values and the influence of the anesthetics on the activity of neuromuscular blockers. When applied as an anesthetic, xenon is thought to act by antagonizing glutamatergic neurotransmission at N-methyl-Daspartate (NMDA) receptors. [27] Electroencephalogram (EEG)-based indices such as BIS are now commonly used to determine the state of hypnosis during general anesthesia, and this practice allows the anaesthesiologist to decrease both the consumption of anesthetics and the incidence of patient awareness. [28] However, since ketamine (another NMDA-receptor antagonist) has been shown to increase BIS values, it seems paradoxical that the anesthesia level is deepened by additional anesthetic agents. [29] [30] [31] Whether BIS levels are always a good indicator for anesthetics acting via NMDA receptors remains uncertain. We therefore evaluated the performance of anesthesia depth monitors by comparing BIS values between the 2 groups across 4 clinical trials. [4] [5] [6] 10] Our results showed that the BIS value was significantly lower in the xenon group than in the propofol group (propofol acts by potentiating g-aminobutyric acid A [GABAA] receptor activity). [32] A possible explanation for this result may be that different mechanisms of anesthetic action are used to produce unconsciousness. Additionally, the lower BIS values that are observed after xenon treatment than after propofol treatment are due to data averaging and technical delay behind the true EEG processes owing to the rapid emergence from xenon anesthesia. Moreover, combined treatment with a GABAergic drug like propofol or sevoflurane may change the EEG pattern and interfere with NMDA antagonist anesthetics to produce inaccurate BIS values as with ketamine. These results suggest that monitoring the BIS index may not be suitable when assessing the depth of xenon-induced anesthesia, although it may be adequate for assessing the effect of propofol. Xenon allows patients to rapidly emerge and recover from anesthesia because of its extremely low blood-gas solubility. [15, 33] Two included RCTs showed that xenon did not affect nondepolarizing muscle relaxation. Moreover, we did not observe any differences in the length of stay in the PACU, which is another recovery index. These results support the claim that xenon is clinically safe and has good efficacy.
We acknowledge that there are limitations to the present metaanalysis. First, only articles that were published in English were retrieved, and the data for most of the comparisons examined in this study were obtained from 4 or fewer studies. Thus, our conclusions may be based on relatively small numbers of patients. Second, there was heterogeneity in some study characteristics, including the types of surgery, patient populations, and perioperative opioid consumption. Finally, the influence of publication bias should be recognized.
In conclusion, xenon has been demonstrated to have good clinical efficacy and safety with regard to recovery time, influence on neuromuscular blockers, and postoperative complications, and it may therefore be a good alternative to general anesthetics. In addition, clinicians must take the higher MAP, lower HR, and lower BIS values associated with xenon into consideration when using this drug instead of propofol as an anesthetic.
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